Financial conflicts of interest in biomedical human subject research.
The purpose of this paper is to examine the past, present and future of financial conflict of interest regulation in biomedical human subject testing. Part I will briefly review the forces giving rise to the current controversy. Part II will examine the more influential ethical codes on human subject testing and argue that they are inconclusive on the subject of financial conflicts of interest. Part III will examine the various regulations now in place and identify their serious flaws. Part IV will critique the leading proposals for reform. The Conclusion will synthesize the best features of the various proposals for reform and suggest improvements left unaddressed by these proposals.
Goldstein
Nathan
N
Boston University School of Law, USA.
D026683:Advisory Committees; D035843:Biomedical Research / Q000191:economics; D016265:Conflict of Interest / Q000191:economics* / Q000331:legislation & jurisprudence; D030881:Disclosure / Q000331:legislation & jurisprudence; D033161:Government Regulation; D017408:Guidelines as Topic; D006805:Human Experimentation / Q000331:legislation & jurisprudence*; D006801:Humans; D007373:Interinstitutional Relations; D012108:Research Personnel / Q000191:economics / Q000331:legislation & jurisprudence; D012926:Social Control, Formal; D012952:Societies; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence; D014492:United States Public Health Service / Q000331:legislation & jurisprudence